WILMINGTON, Mass., Jan. 18, 2022 /PRNewswire/ - Liberty Defense Holdings Ltd. ("Liberty" or the "Company") (TSXV: SCAN) (OTCQB: LDDFF) (FRANKFURT: LD2), a leading technology provider of concealed weapons and threat detection solutions, is pleased to announce that the Company's millimeter-wave shoe screening technology, initially developed at Pacific Northwest National Laboratory (PNNL), was awarded the 2022 Interagency Partnership Award from the Federal Laboratory Consortium for Technology Transfer (FLC).
The annual FLC awards are considered to be among the top honors in the technology transfer field and recognize federal laboratories for outstanding technology transfer achievements. PNNL was honored for its work on the technology, which was developed in partnership with the U.S. Department of Homeland Security, Science and Technology Directorate, and exclusively licensed to Liberty Defense in 2021 for commercialization.
"This is a great accomplishment and a true reflection of the partnership between PNNL and Liberty to bring innovative and next generation security technology to the market," said Bill Frain, CEO of Liberty Defense. "The shoe screening technology, paired with the High-Definition Advanced Imaging Technology body scanner, also licensed to Liberty, will revolutionize screening at aviation checkpoints."
The millimeter-wave shoe scanner uses advanced imaging to detect concealed objects in footwear without the wearer having to remove their shoes, creating a highly efficient, seamless screening process.
"In practice, the shoe screener could be integrated into the floor of the existing airport body scanning portals or be used as a standalone unit at the checkpoint," added Frain. "Our goal is to improve not only the efficacy of airport screening, but also improve the experience of passengers. This technology has the potential to do just that."
In additional news, pursuant to its omnibus long-term incentive plan, and subject to regulatory approval, Liberty has granted a total of 100,000 stock options (the "Options") to an employee and 150,000 restricted share units ("RSUs") to a former officer, effective January 14, 2022. Each Option is exercisable for one common share in the capital of the Company (a "Share") at an exercise price of $0.36 per Share. 12.5% of the Options will vest on April 14, 2022, and an additional 12.5% will vest every three months thereafter. The Options will expire on January 14, 2027. All 150,000 RSUs will vest on January 14, 2023.